WO2006060211A3 - Derives de pyrazole pour le traitement de dysfonctionnement sexuel - Google Patents
Derives de pyrazole pour le traitement de dysfonctionnement sexuel Download PDFInfo
- Publication number
- WO2006060211A3 WO2006060211A3 PCT/US2005/042077 US2005042077W WO2006060211A3 WO 2006060211 A3 WO2006060211 A3 WO 2006060211A3 US 2005042077 W US2005042077 W US 2005042077W WO 2006060211 A3 WO2006060211 A3 WO 2006060211A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sexual dysfunction
- treatment
- pyrazole derivatives
- pyrazole
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'invention concerne des dérivés de pyrazole qui sont utilisés pour le traitement de dysfonctionnement sexuel.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63202904P | 2004-11-30 | 2004-11-30 | |
| US60/632,029 | 2004-11-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2006060211A2 WO2006060211A2 (fr) | 2006-06-08 |
| WO2006060211A3 true WO2006060211A3 (fr) | 2006-12-28 |
Family
ID=36565541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2005/042077 Ceased WO2006060211A2 (fr) | 2004-11-30 | 2005-11-18 | Derives de pyrazole pour le traitement de dysfonctionnement sexuel |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2006060211A2 (fr) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001070700A1 (fr) * | 2000-03-23 | 2001-09-27 | Solvay Pharmaceuticals B.V. | Derives de 4,5-dihydro-1h-pyrazole ayant une activite antagoniste de cb¿1? |
-
2005
- 2005-11-18 WO PCT/US2005/042077 patent/WO2006060211A2/fr not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001070700A1 (fr) * | 2000-03-23 | 2001-09-27 | Solvay Pharmaceuticals B.V. | Derives de 4,5-dihydro-1h-pyrazole ayant une activite antagoniste de cb¿1? |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006060211A2 (fr) | 2006-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006017384A3 (fr) | Indazoles utiles dans le traitement de maladies cardio-vasculaires | |
| WO2009052431A3 (fr) | Agents de liaison au cd19 et utilisations de ceux-ci | |
| WO2007064872A3 (fr) | Composes de l'uree utilises dans le traitement du cancer | |
| WO2006024018A3 (fr) | Methodes et compositions pour le traitement de la douleur nociceptive | |
| WO2007150015A3 (fr) | Procédé de traitement | |
| WO2007092622A3 (fr) | Compositions et méthodes pour le traitement d'os | |
| WO2006071960A3 (fr) | Compositions et procedes de traitement de troubles de la proliferation cellulaire | |
| WO2006119329A3 (fr) | Compositions et procedes pour traiter des maladies neurodegeneratives | |
| WO2006003388A3 (fr) | Compositions et procedes pour le traitement de troubles inflammatoires | |
| WO2008030367A3 (fr) | Inhibiteurs sélectifs de la myostatine | |
| WO2007059202A3 (fr) | Derives de pyrazolyluree utilisables dans le traitement du cancer | |
| WO2006102504A3 (fr) | Combinaisons destinees au traitement de cancer | |
| WO2007109037A3 (fr) | Analogues de thiazolidinedione | |
| WO2007122382A3 (fr) | Lycopène pour le traitement d'une dysmétabolie | |
| WO2009009034A3 (fr) | Procédées et compositions utiles dans le traitement de la mucosite | |
| IL178100A0 (en) | 5-amino-4-hydroxy-7-(1h-indolmethyl)-8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension | |
| IL198941A0 (en) | Isosorbide mononitrate derivatives for the treatment of ocular hypertension | |
| WO2005103010A3 (fr) | Composes chimiques | |
| WO2004098599A3 (fr) | Agents pour le traitement de troubles du bas-ventre | |
| ZA200804443B (en) | Pharmaceutical combinations comprising testosterone in the treatment of female sexual dysfunction | |
| WO2008050133A3 (fr) | Inhibition d'une agrégation de beta-amyloïde | |
| WO2008085927A3 (fr) | Procédés, compositions et kits destinés au traitement de la douleur | |
| WO2006060211A3 (fr) | Derives de pyrazole pour le traitement de dysfonctionnement sexuel | |
| WO2006060199A3 (fr) | Derives d'imidazole utilises dans le traitement des dysfonctionnements sexuels | |
| ZA200805601B (en) | RNAI-mediated inhibition of IGF1R for treatment of ocular angiogenesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 05849396 Country of ref document: EP Kind code of ref document: A2 |